Response to the Letter Regarding “Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues”

Documenti analoghi

• Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues
  di: Hongsheng Yu, et al.
  Pubblicazione: (2025)
• Comment on: “Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(T)ide Analogues”: The Critical Need to Assess Serial Score Changes for Dynamic Risk Stratification
  di: Chunwei Wang, et al.
  Pubblicazione: (2026)
• Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis
  di: Soe Thiha Maung, et al.
  Pubblicazione: (2025)
• Letter to the Editor Regarding “Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C”
  di: Tiancheng Gong
  Pubblicazione: (2025)
• Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease
  di: Hongsheng Yu, et al.
  Pubblicazione: (2024)